https://www.selleckchem.com/pr....oducts/SB-216763.htm
tus was associated with decreased prostate cancer risk. The COVID-19 pandemic challenges multiple sclerosis services to be innovative in delivering infusible therapies. To reduce time in clinical settings, and potential staff or space losses, we implemented rapid infusion protocols for selected patients. To analyse the rate of infusion related reactions and patient experience of rapid infusions of natalizumab and ocrelizumab. To document time reduction patients spent in clinical settings during the COVID-19 pandemic. Patients with pri
Me gusta
Comentario
Compartir
